Zealand Pharma AS (ZLDPF)
(Delayed Data from OTC)
$126.00 USD
0.00 (0.00%)
Updated Aug 28, 2024 12:24 PM ET
2-Buy of 5 2
F Value C Growth D Momentum D VGM
Balance Sheet
Fiscal Year End for Zealand Pharma AS falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 237 | 167 | 227 | 193 | 207 |
Receivables | 20 | 19 | 18 | 9 | 2 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 1 | 0 | 19 | 10 | 0 |
Other Current Assets | 0 | 0 | 10 | 5 | 5 |
Total Current Assets | 258 | 186 | 274 | 218 | 214 |
Net Property & Equipment | 7 | 7 | 14 | 13 | 6 |
Investments & Advances | 3 | 5 | 6 | 8 | 7 |
Other Non-Current Assets | 2 | 3 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 2 | 1 | 0 |
Intangibles | 2 | 0 | 9 | 9 | 0 |
Deposits & Other Assets | 0 | 0 | 3 | 2 | 0 |
Total Assets | 288 | 218 | 329 | 270 | 240 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 39 | 26 | 10 | 11 | 9 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 5 | 0 |
Other Current Liabilities | 0 | 0 | 41 | 37 | 19 |
Total Current Liabilities | 41 | 28 | 53 | 54 | 29 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 2 | 7 | 13 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 57 | 103 | 18 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 3 | 3 | 3 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 56 | 103 | 181 | 82 | 53 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 9 | 7 | 7 | 6 | 5 |
Capital Surplus | 930 | 0 | 676 | 532 | 397 |
Retained Earnings | -711 | 106 | -526 | -351 | -216 |
Other Equity | 3 | 2 | 2 | 1 | 0 |
Treasury Stock | 0 | 0 | 11 | 0 | 0 |
Total Shareholder's Equity | 231 | 116 | 148 | 188 | 186 |
Total Liabilities & Shareholder's Equity | 288 | 218 | 329 | 270 | 240 |
Total Common Equity | 231 | 116 | 148 | 188 | 186 |
Shares Outstanding | 51.50 | 51.50 | NA | 35.80 | 35.80 |
Book Value Per Share | 4.49 | 2.24 | 0.00 | 5.26 | 5.20 |
Fiscal Year End for Zealand Pharma AS falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 471 | 237 | 231 | 247 |
Receivables | NA | 22 | 20 | 54 | 20 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 1 | 2 | 2 |
Other Current Assets | NA | 0 | 0 | 0 | 0 |
Total Current Assets | NA | 493 | 258 | 287 | 269 |
Net Property & Equipment | NA | 7 | 7 | 7 | 7 |
Investments & Advances | NA | 3 | 3 | 3 | 3 |
Other Non-Current Assets | NA | 2 | 2 | 3 | 3 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 2 | 2 | 1 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 522 | 288 | 318 | 299 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 38 | 39 | 35 | 27 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 40 | 41 | 38 | 29 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 40 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 3 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 109 | 56 | 52 | 47 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 9 | 9 | 9 | 9 |
Capital Surplus | NA | 1,144 | 930 | 0 | 0 |
Retained Earnings | NA | -743 | -711 | 255 | 241 |
Other Equity | NA | 3 | 3 | 2 | 3 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 413 | 231 | 265 | 252 |
Total Liabilities & Shareholder's Equity | NA | 522 | 288 | 318 | 299 |
Total Common Equity | 0 | 413 | 231 | 265 | 252 |
Shares Outstanding | 51.50 | 51.50 | 51.50 | 51.50 | 51.50 |
Book Value Per Share | 0.00 | 8.02 | 4.49 | 5.15 | 4.90 |